Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD

10.71

-0.04 (-0.37%)

At close: Oct 30, 2026, 4:00 PM EDT

10.74

+0.03 (0.26%)

After-hours: Oct 30, 2026, 7:56 PM EDT

Xeris Biopharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	335.41	291.85	203.07	163.91	110.25	49.59
Revenue Growth	36.33%	43.72%	23.89%	48.68%	122.32%	142.67%
Cost of Revenue	45.03	42.57	36.83	28.65	22.63	13.32
Gross Profit	290.39	249.28	166.24	135.27	87.61	36.27
Selling, General & Admin	208.14	182.37	163.48	146.1	137.75	116.06
Research & Development	34.81	31.17	25.56	22.34	20.97	25.16
Amortization of Goodwill & Intangibles	10.84	10.84	10.84	10.84	10.84	0.55
Operating Expenses	253.79	224.38	199.88	179.28	169.55	141.77
Operating Income	36.59	24.9	-33.65	-44.01	-81.94	-105.5
Interest Expense	-28.25	-29.08	-30.49	-26.61	-14.1	-7.18
Interest & Investment Income	5.28	4.74	5.32	4.75	2.58	0.73
Other Non Operating Income (Expenses)	-	-	0.01	0	1.76	-0.7
EBT Excluding Unusual Items	13.62	0.55	-58.8	-65.87	-91.7	-112.66
Merger & Restructuring Charges	-	-	-	-	-	-9.66
Gain (Loss) on Sale of Investments	-	-	-	-	-	-0.41
Other Unusual Items	-30.78	-	1.7	2.36	-4.38	-
Pretax Income	-17.17	0.55	-57.1	-63.5	-96.08	-122.73
Income Tax Expense	-	-	-2.27	-1.25	-1.42	-
Net Income	-17.17	0.55	-54.84	-62.26	-94.66	-122.73
Net Income to Common	-17.17	0.55	-54.84	-62.26	-94.66	-122.73
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	168	160	147	138	136	79
Shares Outstanding (Diluted)	168	173	147	138	136	79
Shares Change	10.29%	17.69%	6.61%	1.51%	71.62%	85.32%
EPS (Basic)	-0.10	0.00	-0.37	-0.45	-0.70	-1.55
EPS (Diluted)	-0.10	0.00	-0.37	-0.45	-0.70	-1.55
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	55.67	27.93	-37.85	-49.29	-103.42	-96.62
Free Cash Flow Per Share	0.33	0.16	-0.26	-0.36	-0.76	-1.22
Gross Margin	86.58%	85.41%	81.86%	82.52%	79.47%	73.14%
Operating Margin	10.91%	8.53%	-16.57%	-26.85%	-74.32%	-212.74%
Profit Margin	-5.12%	0.19%	-27.00%	-37.98%	-85.86%	-247.48%
Free Cash Flow Margin	16.60%	9.57%	-18.64%	-30.07%	-93.80%	-194.84%
EBITDA	48.77	37.05	-21.58	-31.68	-69.7	-103.62
EBITDA Margin	14.54%	12.70%	-10.63%	-19.33%	-63.22%	-208.95%
D&A For EBITDA	12.18	12.16	12.07	12.33	12.24	1.88
EBIT	36.59	24.9	-33.65	-44.01	-81.94	-105.5
EBIT Margin	10.91%	8.53%	-16.57%	-26.85%	-74.32%	-212.74%
Revenue as Reported	335.41	291.85	203.07	163.91	110.25	49.59

SEC Filings: 10-K · 10-Q